The p53 Tumor Suppressor Gene Inhibits Angiogenesis by Stimulating the Production of Thrombospondin

  1. K.M. Dameron*,
  2. O.V. Volpert*,
  3. M.A. Tainsky, and
  4. N. Bouck*
  1. *Department of Microbiology-Immunology and Lurie Cancer Center, Northwestern University, Chicago, Illinois 60611; Department of Tumor Biology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 70030

This extract was created in the absence of an abstract.

Excerpt

The proteins encoded by most human tumor suppressor genes are transcription factors or components of signal transduction pathways (Levine 1993). These tumor suppressors impose their antineoplastic phenotype on cells by modulating the expression of other genes. It is the proteins encoded by these suppressor-regulated genes, acting as effector molecules for the suppressor genes, that directly alter the cell or its environment in such a way as to make progression toward malignancy less likely. For example, it is the p53-regulated p21 protein that actually implements the p53-induced cell-cycle block by binding to and inhibiting cyclin/cdk complexes (El-Deiry et al. 1993). We have sought effector proteins that implement phenotypes induced by tumor suppressor genes by studying secreted molecules that regulate new blood vessel growth (neovascularization or angiogenesis), reasoning that they may provide insight into suppressor gene action and simultaneously serve as a starting point for the development of nongenotoxic anticancer therapies.

The...

| Table of Contents